Vontobel Holding Ltd. Cuts Stake in DexCom, Inc. (NASDAQ:DXCM)

Vontobel Holding Ltd. reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 50.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 35,024 shares of the medical device company’s stock after selling 35,562 shares during the period. Vontobel Holding Ltd.’s holdings in DexCom were worth $2,724,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in DXCM. Blue Whale Capital LLP increased its position in shares of DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after purchasing an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC increased its position in shares of DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the last quarter. Brooktree Capital Management purchased a new stake in shares of DexCom in the 3rd quarter valued at approximately $683,000. National Pension Service increased its position in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. purchased a new stake in shares of DexCom in the 3rd quarter valued at approximately $650,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 5.9 %

Shares of NASDAQ:DXCM opened at $89.07 on Monday. The company has a market cap of $34.79 billion, a price-to-earnings ratio of 53.34, a PEG ratio of 2.26 and a beta of 1.14. The firm’s 50-day simple moving average is $82.44 and its 200-day simple moving average is $75.49. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,342 shares of company stock valued at $3,628,069 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Oppenheimer dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein upped their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday. Finally, Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.